Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models

Ksenija Nesic; Katherine Rybinski; Gayanie Ratnayake; Gwo-Yaw Ho; Ratana Lim; Marc Radke; Chloe Neagle; Elizabeth M. Swisher; Matthew J. Wakefield; Holly E. Barker; Keiji Furuuchi; Clare L. Scott; Cassandra J. Vandenberg

doi:10.1002/ctm2.70274

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (3) : e70274 DOI: 10.1002/ctm2.70274

LETTER TO THE JOURNAL

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models

Author information +

History +

PDF

Cite this article

Download citation ▾

Ksenija Nesic, Katherine Rybinski, Gayanie Ratnayake, Gwo-Yaw Ho, Ratana Lim, Marc Radke, Chloe Neagle, Elizabeth M. Swisher, Matthew J. Wakefield, Holly E. Barker, Keiji Furuuchi, Clare L. Scott, Cassandra J. Vandenberg. Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models. Clinical and Translational Medicine, 2025, 15(3): e70274 DOI:10.1002/ctm2.70274

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-923.

[2]	Ho GY, Kyran EL, Bedo J, et al. Epithelial-to-Mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule targeting with eribulin. Cancer Res. 2022;82(23):4457-4473.

[3]	Ho GY, Vandenberg CJ, Lim R, et al. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models. Ther Adv Med Oncol. 2023;15:17588359231208674.

[4]	Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641-661.

[5]	Silverstein J, Karlan B, Herrington N, Konecny G. Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025. Curr Opin Obstet Gynecol. 2025;37(1):5-15.

[6]	Cheng X, Li J, Tanaka K, et al. MORAb-202, an antibody-drug conjugate utilizing humanized anti-human fralpha farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity. Mol Cancer Ther. 2018;17(12):2665-2675.

[7]	Albone EC, Cheng X.; Verdi A, Jacob S, et al. MORAb-109: a site-specific eribulin-conjugated ADC targeting human mesothelin. Ann Oncol. 2020:S491-S492.

[8]	Shimizu T, Fujiwara Y, Yonemori K, et al. First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-alpha-positive advanced solid tumors. Clin Cancer Res. 2021;27(14):3905-3915.

[9]	Furuuchi K, Rybinski K, Fulmer J, et al. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models. Cancer Sci. 2021;112(6):2467-2480.

[10]	Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004;93(1):98-106.

[11]	Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452-464.

[12]	Yin S, Bhattacharya R, Cabral F. Human mutations that confer paclitaxel resistance. Mol Cancer Ther. 2010;9(2):327-335.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.